Steve Clark

Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

GenVec, Inc. (Nasdaq: GNVC) Posts Big Gains

Genvec, Inc. – Nasdaq: GNVC

Genvec, Inc shares rose over 75% in today’s trading. The shares, traded on the Nasdaq under ticker GNVC, ended yesterday at $4.97. Today they rose to a high of $10.44 before ending the session at $8.79. Volumes for GNVC averaged around 100,000 but today volume reached over 17 million.

GenVec is a clinical-stage biopharmaceutical company with an entrepreneurial focus on leveraging its AdenoVerse™ gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The company is a pioneer in the design, testing and manufacture of adenovectored product candidates that can deliver on the promise of gene-based medicine. On January 5th, Genvec, Inc. an exclusive option agreement with Washington University in St. Louis, MO to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting.

A single firm follows Genvec and their analyst gives GNVC a rating of “Strong Buy”. Genvec has never experienced positive EPS and last year reported a loss of $3.90 EPS. While Genvec has reported sales each year since 2011, 2015 represented its weakest year – Genvec posted sales of only $900,000 versus $17.7 million in 2011.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol GNVC
Last Price a/o 4:00 PM EST  $                      8.79
Average Volume 100,000
Market Cap $22.33 million
Sales $600k
Shares Outstanding 2.54 million
Share Float 1.72 million
Shortable Yes
Optionable No
Inside Ownership 1.10%
Short Float 2.25%
Short Interest Ratio 0.39
Quarterly Return 114.39%
YTD Return 173.83%
Year Return 22.08%

Barracuda Networks, Inc. (NYSE: CUDA) Beats Estimates – Rises in After-Hours Market

Barracuda Networks, Inc. – NYSE: CUDA

Barracuda Networks, Inc. beat street earnings estimates and rose over 8% in after-hours trading. Traded on the Nasdaq, CUDA shares rose to an after-hours high of $25.87. Street estimates, on average, were for Barracuda Networks, Inc. to earn $0.15 per share. The Campbell, CA-based company reported $0.22 EPS after posting loss for the same quarter last year. Revenue was also higher than street estimates – $88.8 million vs. $86.9 million.

Barracuda Networks, Inc. offers industry-leading solutions designed to solve mainstream IT problems. Their products span three distinct markets, including: 1) content security, 2) networking and application delivery and 3) data storage, protection and disaster recovery. CitiBank, Coca-Cola, Delta Dental, FedEx, Harvard University, IBM, L’Oreal, Liberty Tax Service, Mythbusters and Spokane Public Schools are among the more than 150,000 organizations in 100+ countries confidently protecting their users, applications and data with Barracuda solutions. Their network has 1000+ employees, 5000+ partners, and offices in 15 countries.

CUDA has reported increasing sales figures every year since 2012 when it reported $160.9 million. In 2016 Barracuda Networks, Inc. reported $320.2 million. Fourteen firms follow CUDA, with eight rating it a “Strong Buy”, one rates it a “Buy”, three rate CUDA as a “Hold”, and two rate it as a “Sell”. Consensus price target amongst analysts is $28.00.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol CUDA
Last Price a/o 7:59 PM EST  $                    25.70
Average Volume 663,430
Market Cap $1.23 Billion
Sales $338.4 million
Shares Outstanding 51.71 million
Share Float 32.48 million
Shortable Yes
Optionable Yes
Inside Ownership 12.50%
Short Float 2.22%
Short Interest Ratio 1.1
Quarterly Return -0.25%
YTD Return 10.92%
Year Return 121.53%

Enteromedics Inc. (Nasdaq: ETRM)

EnteroMedics Inc.– Nasdaq: ETRM

Enteromedics Inc has had four continuous days of gains. Traded on the Nasdaq under ticker ETRM, the biotech stock had a reverse split in late December. What is newsworthy of late is the massive relative volumes that have been associated with the stock. Below is our original report from January 6, 2017.


Shares of MN-based EnteroMedics Inc. are up over 80% in pre-market trading on heavy volume. Shares are traded on the Nasdaq under the ticker symbol ETRM. ETRM closed at $2.09 on Wednesday, $3.97 on Thursday, and have traded as high as $7.62.

EnteroMedics® Inc. develops therapies for obesity. It has developed vBloc® vagal blocking therapy, a patented therapeutic approach to treat a range of gastrointestinal and metabolic diseases. vBloc® is a weight loss treatment that addresses the growing global health crises associated with obesity and its co-morbidities, such as diabetes and hypertension.

vBloc® Therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, controls both hunger and fullness by blocking the primary nerve which regulates the digestive system. The Maestro Rechargeable System has received Food and Drug Administration (FDA) approval as well as CE Mark in Europe, and has been listed on the Australian Register of Therapeutic Goods (ARTG) by the Therapeutic Goods Administration (TGA) for supply in Australia.

Price action seems to be motivated by news that MedStar Health in Maryland and Roper St. Francis in South Carolina, both vBloc institutes, have implanted vBloc Neurometabolic therapies.

EnteroMedics Inc. has no reported sales. Only one firm follows ETRM and rates it as a “Strong Buy”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Immunomedics, Inc. (NASDAQ:IMMU)

Genocea Biosciences Inc. (Nasdaq: GNCA) Reports Phase 2b results – shares up

Genocea Biosciences, Inc. – Nasdaq: GNCA

Genocea Biosciences Inc. reported positive results in a Phase 2b clinical trial. Shares (Nasdaq: GNCa) are up over 13% on the news.

Chip Clark, president and chief executive officer of Genocea stated “We are very pleased to have demonstrated such a powerful impact on genital herpes clinical disease in this trial, supporting the groundbreaking potential of GEN-003 to be the first-ever therapeutic vaccine for a chronic infection and the first advance in the treatment of genital herpes in more than 20 years…”

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immunity. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs.

Five firms follow Gencocea Biosciences Inc. Four rate GNCA as a “Strong Buy” and one rates GNCA a “Buy”. Their consensus pricet target is $15. Genocea Bioscinces reported sales of $700,000 in 2015. This represented a drop from their 2012 reported sales of $2 million. EPS for GNCA have a similar history. Never achieving positive EPS, GNCA had its worst reporting year in 2014 when they lost $2.27 EPS. In 2015 GNCA improved to a loss of $$1,74 EPS.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol GNCA
Last Price a/o 8:50 AM EST $5.15
Average Volume 132,000
Market Cap $130.4 million
Sales 0.50 million
Shares Outstanding 28.74 million
Share Float 24.8 million
Shortable Yes
Optionable Yes
Inside Ownership 0.40%
Short Float 14.15%
Short Interest Ratio 16.56
Quarterly Return 1.79%
YTD Return 10.19%
Year Return -10.63%

Ocular Therapeutix, Inc (Nasdaq: OCUL) Shares up in Pre-Market on Phase 3 Results

OcularTherapeutix, Inc. – Nasdaq: OCUL

Bedford, MA-based Ocular Therapeutix, Inc. shares are up over 8% in pre-market trading. Traded on the Nasdaq under ticker OCUL, the shares are benefitting from positive news that additional positive secondary endpoint results were reached from its most recent successful phase 3 clinical trial of Dextenza™ (dexamethasone insert) 0.4 mg, for the treatment of post-surgical ocular inflammation and pain.

Dextenza is a product candidate administered by a physician as a bioresorbable intracanalicular insert and designed to release drug to the ocular surface for up to 30 days. Dextenza successfully met the trial’s two primary efficacy endpoints, absence of ocular pain on day 8 and absence of ocular inflammation on day 14 when compared to placebo. In this Phase 3 clinical trial, for which the complete safety assessment will be available in the first quarter of 2017, no treatment-related serious adverse events were observed. Dextenza has exhibited a favorable safety profile and has been well tolerated in all clinical trials, regardless of indication.

“The positive results for the secondary endpoint of absence of ocular flare build upon the successful topline results from this trial which we announced last month,” said Jonathan H. Talamo, M.D., Chief Medical Officer of Ocular Therapeutix.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix plans to resubmit an NDA in the first quarter of 2017 for post-surgical pain for its lead product candidate, Dextenza™.

OCUL shares had an EPS loss of $2.69 in 2014 and a loss of $1.71 in 2015. Sales were $0.8 million in 2014 and $1.8 million in 2015. Four firms follow Ocular Therapeutix, Inc. Two give OCUL shares a “Strong Buy” rating and Two give OCUL a rating of “Buy”. Consensus price tagrte is $26.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol OCUL
Last Price a/o 8:37 AM EST $9.09
Average Volume 1.06 million
Market Cap $206 milion
Sales 1.8 million
Shares Outstanding 24.76 million
Share Float 21.79 million
Shortable Yes
Optionable Yes
Inside Ownership 2.70%
Short Float 23.45%
Short Interest Ratio 4.83
Quarterly Return 21.46%
YTD Return -0.60%
Year Return -6.52%

Titan Pharmaceuticals (Nasdaq: TTNP) Up 15%

Titan Pharmaceuticals Inc. – Nasdaq: TTNP

Titan Pharmaceuticals Inc. trades on the Nasdaq under ticker symbol TTNP. Shares are up almost 15% on heavy volumes. Shares closed on Friday at $4.00 and have reached $4.60 in today’s early trading.

Titan Pharmaceuticals develops proprietary therapeutics for the treatment of select chronic diseases utilizing its innovative, long-term, continuous drug delivery platform, ProNeura. ProNeura implants enhance patient care by providing non-fluctuating, stable levels of medication in the blood for up to one year. Titan is in the early stages of product development programs utilizing ProNeura for the treatment of Parkinson’s disease and hypothyroidism. It’s also evaluating the feasibility of additional product candidates that would be suitable for the treatment of several chronic diseases, including certain hormonal deficiencies; type 2 diabetes, attention deficit hyperactivity disorder, benign prostate hyperplasia and others.

One form covers Titan Pharmaceuticals and gives TTNP a rating of “Strong Buy” with a price target of $11. TTNP reached its highs in EPS ($0.65) and sales ($10.5 million) in 2013. It progressively posted worse figures in 2014 and 2015.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Tracon Pharmaceuticals Inc. (Nasdaq: TCON) Reaches FDA Agreement

Tracon Pharmaceuticals Inc. – Nasdaq: TCON

Shares of San Diego, CA-based Tracon Pharmaceuticals Inc. are trading at their daily highs on heavy volumes. TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases.

Traded on the Nasdaq under ticker symbol TCON, the shares gapped up from their previous close of $4.90 on news that the biotechnology firm reached an agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the protocol design, clinical endpoints, and statistical analysis approach for the Company’s Phase 3 study evaluating TRC105 for the treatment of patients with advanced angiosarcoma. The SPA process is one in which a sponsor asks the FDA to evaluate the proposed design and size of Phase 3 clinical trials that are intended to form the primary basis for determining a drug product’s efficacy. An SPA agreement indicates concurrence with the adequacy and acceptability of specific critical elements of protocol design, endpoints and analysis.

Three firms cover Tracon Pharmaceuticals Inc. and all three assign TCON shares a “Strong Buy” with a consensus price target of $12. In 2015 Tracon reported their strongest sales figures yet – $7.9 million but had a EPS loss of $2.20. TCON shares have never experienced positive EPS.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol TCON
Last Price a/o 11:30 AM EST $5.75
Average Volume 47,000
Market Cap $69.78 million
Sales $4.2 million
Shares Outstanding 14.24 million
Share Float 13.51 million
Shortable Yes
Optionable No
Inside Ownership 37.69%
Short Float 0.70%
Short Interest Ratio 2.01
Quarterly Return -26.54%
YTD Return -46.97%
Year Return -46.97%

Fortress Biotech Inc. (Nasdaq: FBIO) Soaring in Pre-Market

Fortress Biotech, Inc. – Nasdaq: FBIO

Shares of Fortress Biotech Inc. are up over 50% on heavy volume in pre-market trading. FBIO, traded on the Nasdaq, closed Wednesday at $2.29, but Thursday pre-market trading has seen the shares hit $3.50. Investors appear to be flocking to FBIO based on reports that a cancer-stricken patient had responded favorably to a treatment developed by Fortress’s Mustang Bio Inc. unit using T-Cells. The reports suggest that the patient had not experienced improvement with traditional approaches.

Dr. Lindsay A. Rosenwald, Fortress Biotech’s Chairman, President and Chief Executive Officer, said, “We are excited to share this unprecedented research conducted by Mustang’s partners at City of Hope, which confirms the potential of MB-101 to be a breakthrough immunotherapeutic targeted against GBM, an almost universally fatal brain tumor. MB-101’s compelling clinical activity adds to the growing pipeline of therapies developed by our Fortress Companies that have the potential to transform the treatment of life-threatening diseases.”

Michael S. Weiss, Mustang Bio’s Executive Chairman, commented, “We are extremely encouraged by the response seen in this patient.  As the first patient ever to receive intraventricular delivery of CAR T cells for brain tumors, we see this as proof of concept that CAR T cells can be delivered safely and with remarkable effect to patients with GBM.  This robust response has prompted the expansion of our Phase 1 study to evaluate intraventricular administration in a larger cohort of patients.  Given the poor outcomes for patients with GBM, we believe if we see additional patients with this type of response that we can explore a possible accelerated approval pathway, similar to that proposed by some of the other CAR T companies, which are targeting different forms of cancer.”

The sole analyst that covers FBIO rates it a “Strong Buy” with a price target of $11. FBIO had traded above $12 in 2013 and Fortress Biotech has never had a positive year of EPS. However, 2015 was the first year Fortress Biotech reported any sales – $900,000. FBIO appears to be a favored target of short-sellers and investors should perform their own due diligence prior to making any investment decisions as biotech shares are notoriously volatile.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol FBIO
Last Price a/o 7:22 AM EST  $                      3.45
Average Volume 90,600
Market Cap $104.84 million
Sales $4.2 million
Shares Outstanding 45.78 million
Share Float 29.28 million
Shortable Yes
Optionable Yes
Inside Ownership 0.80%
Short Float 12.45%
Short Interest Ratio 40.23
Quarterly Return -22.11%
YTD Return -17.92%
Year Return -17.03%


Canadian Solar Inc. (Nasdaq: CSIQ) Up Today

Canadian Solar Inc. – Nasdaq: CSIQ

Shares of Canadian Solar Inc. are up over 6% in today’s trading on heavy volume. The shares trade on the Nasdaq under the symbol CSIQ. CSIQ had traded under $5 in 2012 before going over $40 in 2014. Since then the shares have pulled back despite increasing sales. EPS for CSIQ hit their high in 2014 when Canadian Solar Inc. posted $4.40 EPS. Sales have been more consistent – increasing every year since 2012 and posting $3.47 Billion in 2015.

Founded in 2001 in Canada, Canadian Solar is one of the world’s largest and foremost solar power companies. As a leading manufacturer of solar photovoltaic modules and provider of solar energy solutions, Canadian Solar also has a geographically diversified pipeline of utility-scale power projects in various stages of development. In the past 15 years, Canadian Solar has successfully delivered over 17 GW of premium quality modules to over 90 countries around the world. Furthermore, Canadian Solar is one of the most bankable companies in the solar industry, having been publicly listed on NASDAQ since 2006.

In recent news, Canadian Solar Inc announced on December 19, 2016, that it has secured GBP 49.3 million (US$62.8 million) in a non-recourse term loan facility to refinance a portfolio of 10 solar power plants, with total capacity of 50 megawatts in the United Kingdom. National Westminster Bank (NatWest), a subsidiary of RBS Group, is providing the 18.7-year term facility. Part of the proceeds will be used to repay a construction loan of GBP 28.1 million (US$35.8 million).

Nine analysts cover Canadian Solar Inc. Two rate CSIQ A “Strong Buy”, six rate the shares as a “Hold”, and one has it at “Underperform”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol CSIQ
Last Price a/o 3:29 PM EST  $             13.12
Average Volume 1.67 million
Market Cap $722 million
Sales $3.3 Billion
Shares Outstanding 58.56 million
Share Float 45.3 million
Shortable Yes
Optionable Yes
Inside Ownership 31.00%
Short Float 16.12%
Short Interest Ratio 4.4
Quarterly Return -2.68%
YTD Return -57.42%
Year Return -57.96%

Heat Biologics Inc. (Nasdaq: HTBX) Up in Early Trading on Heavy Volume

Heat Biologics Inc.; Nasdaq: HTBX

Biotechnology firm Heat Biologics, Inc. are up over 20% in early trading on heavy volume. The Durham, NC-based biotechnology firm trades on the Nasdaq under the ticker HTBX. Shares closed yesterday at $0.77 but quickly rose above $0.90 in the first thirty minutes of trading.

Heat Biologics is a clinical-stage biotechnology company focused on developing its novel off-the-shelf ImPACT therapeutic vaccines to combat a wide range of cancers and infectious diseases. ImPACT Therapy exploits the natural ability of antigens to activate the immune system by utilizing live, irradiated, off-the-shelf, genetically modified cells injected into a patient designed to elicit a powerful immune response against the disease target. Heat biologics is currently conducting multiple clinical trials in two indications with its ImPACT therapy based products, HS-410 to treat Non-Muscle Invasive Bladder Cancer (NMIBC) and HS-110 to treat Non-Small Cell Lung Cancer (NSCLC).

In a December 6, 2016 press release, Heat Biologics Inc. stated that principal investigator, Daniel Morgensztern, MD, Associate Professor of Medicine and Director of Thoracic Oncology, Washington University School of Medicine, reported that one-year results from the first eight trial patients showed that the HS-110/nivolumab combination was well-tolerated, with a safety profile consistent with single agent nivolumab.

“These new data are further confirmation of the ability of our ImPACT platform, which has been administered to over 200 patients in 4 clinical studies, to generate a robust antigen-specific immune response, an important component of immunotherapy,” said Jeff Wolf, Heat’s CEO.  “The future of immuno-oncology lies in combining synergistic modalities to create more effective treatments. At Heat, we are actively pursuing opportunities to combine our ImPACT and ComPACT platforms with checkpoint inhibitors, and other promising immunotherapies to improve patient outcomes.”

One analyst follows Heat Biologics, Inc. and assigns a “Strong Buy” rating to HTBX with a price target of $4.00.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol HTBX
Last Price a/o 10:16 AM EST  $                    0.92
Average Volume 2.38 million
Market Cap $17.79 million
Sales $0.20 million
Shares Outstanding 23.23 million
Share Float 21.66 million
Shortable No
Optionable No
Inside Ownership 30.02%
Short Float 8.42%
Short Interest Ratio 0.76
Quarterly Return -45.29%
YTD Return -68.61%
Year Return -67.54%